Clinical trials located in

Nadarzyn

Nadarzyn city is located in Poland. Currently, 6 clinical trials are being conducted in this city.

Nadarzyn, a quaint town in Poland, is nestled within the Masovian Voivodeship, near Warsaw. Known for its blend of modernity and tradition, it hosts the Ptak Warsaw Expo, the largest trade fair and exhibition venue in Poland. Despite its small size, Nadarzyn is rich in green spaces and local history, with the Church of St. Clement dating back to the early 20th century. The town also thrives on agriculture, contributing significantly to the local economy. Its proximity to the capital allows for a harmonious mix of rural calm and urban accessibility.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A new drug trial for the treatment of lupus

    This research studies a new drug, ESK-001, for adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial will compare ESK-001’s effectiveness and safety against a placebo over 48 weeks. It will involve 388 participants, randomized to receive either ESK-001 or a placebo. The main focus is to see if ESK-001 can reduce lupus symptoms and improve quality of life. Researchers will also monitor any side effects and overall safety of the drug.

    • ESK-001- new potential medication for autoimmune disorders
  • Psoriatic arthritis study with tildrakizumab

    The trial is enrolling participants with psoriatic arthritis to continue treatment with tildrakizumab, an injectable drug. This is an open-label Phase 3 study that focuses on the drug’s long-term effects and aims to track any side effects and its effectiveness in helping to treat arthritis symptoms. The aim is to better understand the effectiveness of tildrakizumab over the long term and ensure it can be used safely on an ongoing basis.

    • Tildrakizumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.